Immune profile of patients with reticuloplasmocytoma treated with alkeran and prednisone.
The humoral and cellular immune response was examined in 26 patients with reticuloplasmocytoma. In 14 patients the tests were repeated after 6-8 month treatment with Alkeran and Prednisone. The following parameters were determined: level of immunoglobulin G, A and M, lymphocyte count and differential count (T, B and O), leukocytes migration tests and tuberculine skin test. It appeared from our studies, that patients with reticuloplasmocytoma have defects in humoral and cellular responses, however, the treatment applied, did not influence any of the measured parameters.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D002464:Cell Migration Inhibition; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007136:Immunoglobulins / Q000032:analysis*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010954:Plasmacytoma / Q000188:drug therapy / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use; D012882:Skin Tests
D000903:Antibiotics, Antineoplastic; D007136:Immunoglobulins; D011241:Prednisone